← Leaderboards
Stephen Parent
Kathera Bioscience Inc.
$2,189,220
Attributed
$2,189,220
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $995.1K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,189,220 · 3
By mechanism
R44$1,293,630 · 1
R43$895,590 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Life”
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Martha Hering · Westat, Inc.$57,098,843
Research focus
LifePharmaceutical PreparationsLead OptimizationEmerging PathogenMycosesPathogenic FungusDrug InteractionsGeneticDrug ResistanceDrug TargetingMembraneGrowthDependenceAspergillusAnalogCellsDrug DevelopmentCandida AlbicansCandidaClinical DiagnosisBiochemicalCell WallLeadPrograms
Grant awards (5)
Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens$995,100
R44 · FY2025 · AI · contact PI
Novel Broad Spectrum Inhibitors of Dihydrofolate Reductase (DHFR) for Treatment of Infections from High Threat Fungal Pathogens$298,530
R44 · FY2024 · AI · contact PI
A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infections$298,530
R43 · FY2024 · AI · contact PI
A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infections$298,530
R43 · FY2023 · AI · contact PI
Ess1: A pathogenic fungal target for a novel class of broad-spectrum therapeutic agents$298,530
R43 · FY2021 · AI · contact PI